Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|February 2, 2005
- Pharmaceutical Technology-02-02-2005
- Volume 29
- Issue 2
Contract Manufacturers Getting Squeezed
Author(s)Jim Miller
Too many players and threats to the main customer base challenge European dose manufacturers.
Advertisement
Articles in this issue
over 21 years ago
Correcting the Courseover 21 years ago
February 2005over 21 years ago
Good Work and True: USP Prepares for Convention 2005over 21 years ago
In the Spotlight-February 2005over 21 years ago
Emerging Analytical Technology: Moving from the Lab to the Lineover 21 years ago
Drug Safety Fears May Limit Reimporting and Shape R&Dover 21 years ago
In Defense of USP Singlet TestingAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement